Search Results for “diagnostic” – Page 50 – media

Acurable prepares to challenge ResMed for sleep apnea diagnosis market

Dive Brief Acurable is preparing to challenge ResMed and Resonea for the sleep apnea diagnosis market in the U.S. Having received 510(k) clearance in February, Acurable plans to start selling its AcuPebble Ox100 device in the U.S. this summer. The device records the sounds of the patient’s respiratory and cardiac functions and monitors blood oxygen levels to assess suspected obstructive sleep apnea. ResMed acquired a rival device, now sold as onesleeptest, through its 2021 Ectosense takeover and Resonea offers some of the same capabilities through its Drowzle Pro mobile application. Dive Insight AcuPebble Ox100 builds on an older Acurable device, AcuPebble SA100, that received 510(k) clearance in the summer of 2021. Like the older device, AcuPebble Ox100 features a sensor that the patient sticks to their neck to record respiratory and heart sounds. The acoustic signals are processed and analyzed by algorithms to detect sleep apnea. The new device combines ...
- Source: https://www.medtechdive.com/news/acurable-launch-sleep-apnea-diagnosis/651232/
- 103
- May 28, 2023
FDA clears insertable cardiac monitor from Abbott

Abbott (NYSE:ABT) today announced that it received FDA clearance for its Assert-IQ insertable cardiac monitor (ICM). The Assert-IQ device offers a new option for diagnostic evaluation and long-term monitoring for irregular heartbeats. It supplements Abbott’s portfolio of connected health devices for managing and treating patients remotely. The device could potentially rival the Medtronic Linq system. A small device with sensors inserted just under the skin of the chest, Assert-IQ provides constant, real-time monitoring. It can detect and identify arrhythmias that lead to symptoms like fainting, irregular pulse and shortness of breath. Abbott says many commercially available ICMs monitor hearts for “a few years,” but Assert-IQ offers two options. With a battery life of at least three or six years, it can provide doctors with a new level of flexibility in diagnostic monitoring. The three-year option offers a method for more traditional monitoring. That includes diagnosing fainting, heart palpitations or abnormal ...
- Source: drugdu
- 119
- May 20, 2023
Abbott expands initiative to increase diversity in clinical trials

May 12, 2023 By Sean Whooley Leave a Comment Abbott (NYSE:ABT) announced a new series of programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care in under-represented populations. The additions to Abbott’s “Diversity in Clinical Trials” initiative build on partnerships, scholarships and the focus on diversified patients. Abbott applied these to its own clinical trials throughout the initiative’s first year. Within that first year, the company established a Diversity in Clinical Trials Medical Advisory Board. Through $5 million in grants, it also sponsored more than 300 scholarships at four historically black colleges and university (HBCU) medical schools, plus the National Black Nurses Association and National Association of Hispanic Nurses. Within this program expansion, Abbott launched a new initiative with the Norton Healthcare Foundation. It aims to build and implement new models of sustainable clinical research alongside the Institute for Health Equity in Louisville, Kentucky. ...
- Source: drugdu
- 141
- May 16, 2023
A machine-learning approach for the early diagnosis of Parkinson’s disease

By Dr. Priyom Bose, Ph.D.May 11 2023Reviewed by Benedette Cuffari, M.Sc. Among all neurological diseases, the incidence of Parkinson’s disease (PD) has increased significantly. PD is typically diagnosed on the basis of motor nerve symptoms, such as resting tremors, rigidity, and bradykinesia. However, the detection of non-motor symptoms, such as constipation, apathy, loss of smell, and sleep disorders, could help in the early diagnosis of PD by several years to decades. In a recent ACS Central Science study, scientists from the University of New South Wales (UNSW) discuss a machine learning (ML)-based tool that can detect PD years before the first onset of symptoms. Study: Interpretable Machine Learning on Metabolomics Data Reveals Biomarkers for Parkinson’s Disease. Image Credit: SomYuZu / Shutterstock.com Background At present, the overall diagnostic accuracy for PD based on motor symptoms is 80%. This accuracy could be increased if PD was diagnosed based on biomarkers rather than primarily depending on physical symptoms. Several ...
- Source: https://www.news-medical.net/news/20230511/A-machine-learning-approach-for-the-early-diagnosis-of-Parkinsons-disease.aspx
- 109
- May 14, 2023
Maximizing the Value of AI in Cancer Care

Real-time patient experiences is the missing element to most electronic health records, artificial intelligence, and machine learning models today. Anish Patankar, SVP, GM, Oncology Informatics Software, Elekta Cancer treatment has come a long way in recent years and is now evolving more rapidly through the integration of artificial intelligence (AI) tools, such as machine learning (ML). Currently, health data exists in many forms, including electronic health records (EHR), diagnostic images, genomic and molecular data, pharmacological data, and patient-reported data. The creation of state-of-the-art cancer treatments can be enhanced by the ways clinicians leverage data to optimize care, and there’s no better way to achieve this than through the use of AI. Completing the picture There is a missing element to most EHR, AI, and ML models today – real-time patient-reported outcomes. This type of data refers to information regarding patients’ experiences with their medical conditions, treatments, and healthcare providers, ...
- Source: drugdu
- 150
- May 14, 2023
First Of Its Kind Urine Biomarker Methylation Test Predicts Bladder Cancer Recurrence

By LabMedica International staff writers Bladder EpiCheck is the first urine biomarker methylation test of its kind to be FDA cleared for NMIBC surveillance (Photo courtesy of Nucleix) Bladder cancer ranks as the sixth most common cancer in the U.S., with around 700,000 individuals living with the disease and over 80,000 new cases detected each year. The majority of these cases are classified as non-muscle invasive bladder cancer (NMIBC). Although NMIBC can be treated surgically and therapeutically, it has a high recurrence rate (up to 70% over five years), necessitating frequent monitoring to detect high-grade recurrence and treat it promptly. The standard of care involves regular and invasive cystoscopies, which patients undergo up to four times annually for a minimum of five years or, in some cases, for their entire lives. Now, a simple, objective urine test for recurrent bladder cancer is set to become commercially available in the ...
- Source: drugdu
- 119
- May 11, 2023
World-First Smartphone-Powered 5 Marker Lipid Test Aids in Early Detection of Cardiovascular Diseases

By LabMedica International staff writers Image: PocDoc offers the world’s first app based five marker lipid test (Photo courtesy of PocDoc) Cardiovascular disease (CVD), accountable for 32% of global deaths annually, is the world’s leading cause of death. These largely preventable fatalities highlight the urgent need for improved access to CVD testing and subsequent treatment, a pressing concern worldwide. Now, an innovative diagnostic tool for CVD enables early detection by facilitating accurate blood testing via a smartphone or tablet, with results accessible through an app. PocDoc (Cambridge, UK) has pioneered a groundbreaking smartphone-based lipid test capable of delivering a 5 marker lipid panel via the PocDoc app in under six minutes, with results instantaneously shared with the healthcare system. This technology allows lipid testing to extend beyond the confines of general practice surgeries, thereby drastically enhancing accessibility to testing and subsequently preventing more individuals from developing CVD. Despite its ...
- Source: drugdu
- 126
- May 9, 2023
Kry showcases digital care pathways

Systems will support millions of patients with chronic respiratory conditions throughout Europe Kry – a company focused on digital healthcare – is launching a number of digital care pathways to transform treatment approaches for chronic respiratory diseases (CRDs) such as asthma, lung cancer and chronic obstructive pulmonary disease (COPD). The new pathways will help early diagnosis, prevention and wider management of the conditions. It is also hoped that integrated digital healthcare can complement and enhance primary care access. An estimated 235 million people suffering from asthma, while more than 200 million people are living with COPD across the world. Currently, in Sweden, improving access to national screening programs for lung cancer is vital, especially when encouraging better prevention through early detection and establishing treatments. With this considered, Kry is developing a testing and diagnostic solution which uses track and trace in order to assist patients. This enables them be assessed ...
- Source: drugdu
- 119
- May 7, 2023
BioSenic progresses cGvHD system and submits patent to EPO

Patent will allow the development of an industrial biomarker analysis kit which could be available worldwide. BioSenic – a company focusing on in autoimmune and inflammatory diseases – has announced that it has submitted a vital patent in relation to the use of its ATO platform. The patent is referred to as a ‘Diagnostic method for detecting the pathological correlates of chronic graft-versus-host disease (cGvHD) using particular cytokine or chemokine biomarkers’ and has duly been submitted to the European Patent Office desk for consideration. It also covers the use of a quantitative system of evaluating the impact of medications developed to change the course of cGvHD. Two years ago, BioSenic successfully concluded a national multi-location, single-arm phase 2 study in five university hospitals across France. During the trial, BioSenic treated 21 cGvHD patients with an intravenous formulation known as Arscimed. Subsequently, BioSenic published positive efficacy and safety results in the ...
- Source: drugdu
- 129
- May 6, 2023
Wearable ultrasound researchers report breakthrough in deep tissue monitoring

This wearable ultrasound device for monitoring tissue stiffness measures 23 mm x 20 mm x 0.8 mm. [Photo courtesy of University of California San Diego] Wearable ultrasound researchers have developed a stretchable ultrasonic array for serial, noninvasive, 3-D tissue imaging with a penetration depth of up to 4 cm. The latest device out of Sheng Xu’s lab at the University of California San Diego (UCSD) is able to frequently evaluate the stiffness of human tissue. It could be used to measure the progression of cancer, to monitor muscles, tendons and ligaments, and assess the effectiveness of liver and cardiovascular treatments. Xu is commercializing the technology through a UCSD spinoff called Softsonics. “We integrated an array of ultrasound elements into a soft elastomer matrix and used wavy serpentine stretchable electrodes to connect these elements, enabling the device to conform to human ...
- Source: drugdu
- 136
- May 5, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.